Published in Nat Rev Gastroenterol Hepatol on March 22, 2011
Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa | NCT02060162
Exosomes mediate the cell-to-cell transmission of IFN-α-induced antiviral activity. Nat Immunol (2013) 2.64
GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology (2013) 2.14
Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med (2013) 2.02
Intrahepatic Transcriptional Signature Associated with Response to Interferon-α Treatment in the Woodchuck Model of Chronic Hepatitis B. PLoS Pathog (2015) 1.49
Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean. PLoS One (2012) 1.44
Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. Curr Cancer Drug Targets (2012) 1.23
Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections. Hepatology (2015) 1.19
The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes. PLoS Pathog (2013) 1.18
Transcriptomic analysis of the woodchuck model of chronic hepatitis B. Hepatology (2012) 1.10
Interferons: Success in anti-viral immunotherapy. Cytokine Growth Factor Rev (2014) 0.98
Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents. PLoS Pathog (2014) 0.98
Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B. J Hepatol (2015) 0.96
Natural Killer Cells in Viral Hepatitis. Cell Mol Gastroenterol Hepatol (2015) 0.96
Identification of an intrahepatic transcriptional signature associated with self-limiting infection in the woodchuck model of hepatitis B. Hepatology (2013) 0.93
Current status in the therapy of liver diseases. Int J Mol Sci (2014) 0.87
Genetically altering the thermodynamics and kinetics of hepatitis B virus capsid assembly has profound effects on virus replication in cell culture. J Virol (2013) 0.87
Precore mutation of hepatitis B virus may contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. PLoS One (2012) 0.87
Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity. Antiviral Res (2014) 0.86
In vivo models of hepatitis B and C virus infection. FEBS Lett (2016) 0.85
How further suppression of virus replication could improve current HBV treatment. Expert Rev Anti Infect Ther (2013) 0.85
Association of preexisting drug-resistance mutations and treatment failure in hepatitis B patients. PLoS One (2013) 0.82
Gene therapeutic approaches to inhibit hepatitis B virus replication. World J Hepatol (2015) 0.82
Studies of efficacy and liver toxicity related to adeno-associated virus-mediated RNA interference. Hum Gene Ther (2013) 0.82
Residues Arg703, Asp777, and Arg781 of the RNase H domain of hepatitis B virus polymerase are critical for viral DNA synthesis. J Virol (2013) 0.82
Heteroaryldihydropyrimidine (HAP) and Sulfamoylbenzamide (SBA) Inhibit Hepatitis B Virus Replication by Different Molecular Mechanisms. Sci Rep (2017) 0.81
Antiviral Efficacy and Host Innate Immunity Associated with SB 9200 Treatment in the Woodchuck Model of Chronic Hepatitis B. PLoS One (2016) 0.81
The hepatitis B virus ribonuclease H as a drug target. Antiviral Res (2015) 0.81
Hepatitis B: future curative strategies. Curr Opin Infect Dis (2014) 0.81
Hepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genes. World J Gastroenterol (2016) 0.81
Hepatitis B virus efficiently infects non-adherent hepatoma cells via human sodium taurocholate cotransporting polypeptide. Sci Rep (2015) 0.80
Hepatitis B virus management to prevent reactivation after chemotherapy: a review. Support Care Cancer (2012) 0.79
Short-term spontaneous fluctuations of HBV DNA levels in a Senegalese population with chronic hepatitis B. BMC Infect Dis (2015) 0.79
Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy. World J Gastroenterol (2015) 0.79
Getting to grips with hepatitis. Elife (2012) 0.79
Design of therapeutic vaccines: hepatitis B as an example. Microb Biotechnol (2011) 0.79
Molecular docking studies of phytochemicals from Phyllanthus niruri against Hepatitis B DNA Polymerase. Bioinformation (2015) 0.79
The Smc5/6 Complex Restricts HBV when Localized to ND10 without Inducing an Innate Immune Response and Is Counteracted by the HBV X Protein Shortly after Infection. PLoS One (2017) 0.79
Molecular dissection of HBV evasion from restriction factor tetherin: A new perspective for antiviral cell therapy. Oncotarget (2015) 0.78
Antiviral natural products and herbal medicines. J Tradit Complement Med (2014) 0.78
Metabolic characterization of the natural progression of chronic hepatitis B. Genome Med (2016) 0.78
The enzymes LSD1 and Set1A cooperate with the viral protein HBx to establish an active hepatitis B viral chromatin state. Sci Rep (2016) 0.77
Purification and enzymatic characterization of the hepatitis B virus ribonuclease H, a new target for antiviral inhibitors. Antiviral Res (2016) 0.77
Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment. Antimicrob Agents Chemother (2015) 0.77
Reversible bilateral ototoxicity in a patient with chronic hepatitis B during peginterferon alpha-2a treatment. Indian J Pharmacol (2015) 0.77
Antiviral Efficacy and Host Immune Response Induction during Sequential Treatment with SB 9200 Followed by Entecavir in Woodchucks. PLoS One (2017) 0.76
Hepatitis B virus genetic diversity has minimal impact on sensitivity of the viral ribonuclease H to inhibitors. Antiviral Res (2016) 0.76
Current Landscape of Antiviral Drug Discovery. F1000Res (2016) 0.76
Genetic variation in the vitamin D pathway CYP2R1 gene predicts sustained HBeAg seroconversion in chronic hepatitis B patients treated with pegylated interferon: A multicenter study. PLoS One (2017) 0.75
Future Therapy for Hepatitis B Virus: Role of Immunomodulators. Curr Hepatol Rep (2016) 0.75
Persistent human hepatitis B virus infection in cynomolgus monkeys: a novel animal model in the search for a cure? Hepatology (2013) 0.75
Hepatitis B Virus-HIV Coinfection: Forgotten but Not Gone. Gastroenterol Hepatol (N Y) (2014) 0.75
IFIT1 polymorphisms predict interferon-α treatment efficiency for hepatitis B virus infection. World J Gastroenterol (2016) 0.75
A predictive model for carcinogenesis in patients with chronic hepatitis B undergoing entecavir therapy and its validation. Medicine (Baltimore) (2016) 0.75
Expression of Interferon Effector Gene SART1 Correlates with Interferon Treatment Response against Hepatitis B Infection. Mediators Inflamm (2016) 0.75
AIC649 Induces a Bi-Phasic Treatment Response in the Woodchuck Model of Chronic Hepatitis B. PLoS One (2015) 0.75
Duck Hepatitis B Virus cccDNA Amplification Efficiency in Natural Infection Is Regulated by Virus Secretion Efficiency. PLoS One (2015) 0.75
Onychomycosis Case Developing during Interferon Treatment. Balkan Med J (2013) 0.75
Clinical correlation between HBV infection and concomitant bacterial infections. Sci Rep (2015) 0.75
Transcriptome Analysis and Comparison of Marmota monax and Marmota himalayana. PLoS One (2016) 0.75
The role of exosomes in hepatitis, liver cirrhosis and hepatocellular carcinoma. J Cell Mol Med (2017) 0.75
Hepatitis B viral breakthrough associated with inappropriate preservation of entecavir. Indian J Pharmacol (2012) 0.75
Identifying and Characterizing Interplay between Hepatitis B Virus X Protein and Smc5/6. Viruses (2017) 0.75
Dual oncogenic and tumor suppressor roles of the promyelocytic leukemia gene in hepatocarcinogenesis associated with hepatitis B virus surface antigen. Oncotarget (2016) 0.75
Comparison of FIB-4 index and aspartate aminotransferase to platelet ratio index on carcinogenesis in chronic hepatitis B treated with entecavir. J Cancer (2017) 0.75
IFN-α-mediated Base Excision Repair Pathway Correlates with Antiviral Response Against Hepatitis B Virus Infection. Sci Rep (2017) 0.75
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med (2006) 7.35
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med (2006) 5.65
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology (2005) 3.95
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol (2013) 3.41
Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol (2005) 3.18
NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology (2002) 2.96
GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol (2005) 2.70
Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev (2012) 2.57
Hospital readmissions among patients with decompensated cirrhosis. Am J Gastroenterol (2011) 2.49
Outcomes of living donor liver transplantation for acute liver failure: the adult-to-adult living donor liver transplantation cohort study. Liver Transpl (2008) 2.30
Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology (2007) 2.11
Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology (2003) 2.05
CD73 (ecto-5'-nucleotidase) hepatocyte levels differ across mouse strains and contribute to mallory-denk body formation. Hepatology (2013) 2.04
One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol (2005) 2.04
Modified Charlson comorbidity index for predicting survival after liver transplantation. Liver Transpl (2007) 1.96
Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology (2015) 1.87
Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology (2009) 1.80
Liver transplantation for erythropoietic protoporphyria liver disease. Liver Transpl (2005) 1.76
Energy determinants GAPDH and NDPK act as genetic modifiers for hepatocyte inclusion formation. J Cell Biol (2011) 1.72
Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark (2007) 1.65
Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl (2007) 1.61
Renal outcomes after liver transplantation in the model for end-stage liver disease era. Liver Transpl (2009) 1.49
Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl (2005) 1.47
Liver transplantation outcomes among Caucasians, Asian Americans, and African Americans with hepatitis B. Liver Transpl (2009) 1.46
Burden of cirrhosis on older Americans and their families: analysis of the health and retirement study. Hepatology (2012) 1.44
Machine learning algorithms outperform conventional regression models in predicting development of hepatocellular carcinoma. Am J Gastroenterol (2013) 1.39
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology (2011) 1.33
An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data. Liver Transpl (2009) 1.31
Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis B antiviral resistance. J Hepatol (2008) 1.25
A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology (2013) 1.21
Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol (2011) 1.20
SRM targeted proteomics in search for biomarkers of HCV-induced progression of fibrosis to cirrhosis in HALT-C patients. Proteomics (2012) 1.11
An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C. PLoS One (2011) 1.04
Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology (2009) 1.03
Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial. J Hepatol (2005) 0.98
Does antiviral therapy prevent hepatocellular carcinoma? Antivir Ther (2011) 0.92
Impaired virion secretion by hepatitis B virus immune escape mutants and its rescue by wild-type envelope proteins or a second-site mutation. J Virol (2012) 0.90
Mallory-Denk bodies are associated with outcomes and histologic features in patients with chronic hepatitis C. Clin Gastroenterol Hepatol (2011) 0.90
Hepatitis B screening and vaccination practices in asian american primary care. Gut Liver (2013) 0.89
Monitoring antiviral resistance in patients receiving nucleos(t)ide analog therapies for hepatitis B: which method should be used? J Hepatol (2008) 0.89
Clinical relevance of cognitive scores in hepatitis C patients with advanced fibrosis. J Clin Exp Neuropsychol (2006) 0.88
CDC and USPSTF 2012 recommendations for screening for hepatitis C virus infection: overview and take-home messages. Clin Gastroenterol Hepatol (2013) 0.88
Who decides? Living donor liver transplantation for advanced hepatocellular carcinoma. Transplantation (2006) 0.86
Hepatitis B prevalence among Asian Americans in Michigan: an assessment to guide future education and intervention strategies. J Community Health (2010) 0.83
Histologic outcomes in hepatitis C-infected patients with varying degrees of virologic response to interferon-based treatments. Hepatology (2010) 0.82
Impact of the hepatitis B virus genotype on pre- and post-liver transplantation outcomes. Liver Transpl (2008) 0.81
New approaches to optimize treatment responses in chronic hepatitis B. Antivir Ther (2010) 0.80
Interferon-free treatment regimens for hepatitis C: are we there yet? Gastroenterology (2011) 0.80
Predicting cirrhosis and clinical outcomes in patients with advanced chronic hepatitis C with a panel of genetic markers (CRS7). Pharmacogenet Genomics (2011) 0.80
YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C. Liver Int (2011) 0.79
Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C. Am J Gastroenterol (2012) 0.78
A comparative study of patients' attitudes toward clinical research in the United States and urban and rural China. Clin Transl Sci (2015) 0.78
No increase in depression with low-dose maintenance peginterferon in prior non-responders with chronic hepatitis C. J Affect Disord (2011) 0.78
CDC and USPSTF 2012 recommendations for screening for hepatitis C virus infection: overview and take-home messages. Gastroenterology (2013) 0.77
Should antiviral treatment be extended to patients with chronic hepatitis B and mildly elevated alanine aminotransferase? Hepatology (2010) 0.75
What is the optimal regimen for preventing hepatitis B recurrence after liver transplantation? Nat Clin Pract Gastroenterol Hepatol (2008) 0.75
Do guidelines preclude hepatitis B patients from receiving treatment? Hepatology (2009) 0.75
Should liver biopsies be performed on all hepatitis B carriers? Gastroenterology (2008) 0.75
Reply to Giannini and Trevisani. Am J Gastroenterol (2013) 0.75
Should treatment of hepatitis B patients be based solely on liver fibrosis? Clin Gastroenterol Hepatol (2013) 0.75
A comparative study of patients' knowledge about hepatitis C in the United States and in urban and rural China. Hepatol Int (2014) 0.75
Authorship: who should be included and how should it be determined? Gastroenterology (2011) 0.75
Population-Based Analysis and Projections of Liver Supply Under Redistricting. Transplantation (2017) 0.75